Skip to main content
Erschienen in: Journal of Interventional Cardiac Electrophysiology 2/2018

04.08.2018

Left atrial thrombus despite continuous direct oral anticoagulant or warfarin therapy in patients with atrial fibrillation: insights into rates and timing of thrombus resolution

verfasst von: Michael S. Wu, James Gabriels, Mohammad Khan, Nada Shaban, Salvatore A. D’Amato, Christopher F. Liu, Steven M. Markowitz, James E. Ip, George Thomas, Parmanand Singh, Bruce B. Lerman, Apoor Patel, Jim W. Cheung

Erschienen in: Journal of Interventional Cardiac Electrophysiology | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Left atrial thrombus (LAT) may be detected by transesophageal echocardiography (TEE) in patients with atrial fibrillation (AF) or flutter (AFL) despite continuous anticoagulation therapy. We sought to examine the rates and timing of LAT resolution in response to changes in anticoagulation regimen.

Methods

A retrospective study of 1517 consecutive patients on ≥ 4 weeks continuous oral anticoagulation (OAC) undergoing TEE prior to either direct current cardioversion or catheter ablation for AF or AFL was performed. Patients who had LAT on index TEE imaging and had follow-up TEEs were analyzed.

Results

Despite ≥ 4 weeks of continuous anticoagulation therapy, 63 (4.2%) patients had LAT. Forty-four patients (median age 67 [IQR 58, 74]; 33 [75%] male; 25 [57%] on direct oral anticoagulant [DOAC]) had follow-up TEEs performed. Upon detection of LAT on index TEE, 8 patients switched from warfarin to a DOAC, 21 patients switched from a DOAC to warfarin or another DOAC, and 15 patients remained on the same OAC. Over median 4.2 months (IQR 2.9, 6.6), LAT resolution was seen in 25 (57%) patients. Of the 25 patients who had LAT resolution, 7 (28%) required TEE imaging > 6 months after index TEE to show clearance of thrombus. Rates of LAT resolution were similar between patients who had alterations in OAC and those who did not (52 vs. 60%; P = 0.601).

Conclusions

After initial detection of left atrial thrombus despite uninterrupted anticoagulation for atrial fibrillation or flutter, > 40% patients have persistent clot despite additional extended anticoagulation.
Literatur
2.
Zurück zum Zitat Manning WJ, Silverman DI, Gordon SP, Krumholz HM, Douglas PS. Cardioversion from atrial fibrillation without prolonged anticoagulation with use of transesophageal echocardiography to exclude the presence of atrial thrombi. N Engl J Med. 1993;328:750–5.CrossRefPubMed Manning WJ, Silverman DI, Gordon SP, Krumholz HM, Douglas PS. Cardioversion from atrial fibrillation without prolonged anticoagulation with use of transesophageal echocardiography to exclude the presence of atrial thrombi. N Engl J Med. 1993;328:750–5.CrossRefPubMed
3.
Zurück zum Zitat Seidl K, Rameken M, Drogemuller A, Vater M, Brandt A, Schwacke H, et al. Embolic events in patients with atrial fibrillation and effective anticoagulation: value of transesophageal echocardiography to guide direct-current cardioversion. Final results of the Ludwigshafen observational cardioversion study. J Am Coll Cardiol. 2002;39:1436–42.CrossRefPubMed Seidl K, Rameken M, Drogemuller A, Vater M, Brandt A, Schwacke H, et al. Embolic events in patients with atrial fibrillation and effective anticoagulation: value of transesophageal echocardiography to guide direct-current cardioversion. Final results of the Ludwigshafen observational cardioversion study. J Am Coll Cardiol. 2002;39:1436–42.CrossRefPubMed
4.
Zurück zum Zitat Frenkel D, Al-Kazaz M, Markowitz SM, Liu CF, Thomas G, Ip JE, et al. Prevalence of left atrial thrombus by transesophageal echocardiography: a comparison of continuous non-vitamin k antagonist oral anticoagulant versus warfarin therapy in patients undergoing catheter ablation for atrial fibrillation. JACC Clin Electrophysiol. 2016;2:295–303.CrossRefPubMed Frenkel D, Al-Kazaz M, Markowitz SM, Liu CF, Thomas G, Ip JE, et al. Prevalence of left atrial thrombus by transesophageal echocardiography: a comparison of continuous non-vitamin k antagonist oral anticoagulant versus warfarin therapy in patients undergoing catheter ablation for atrial fibrillation. JACC Clin Electrophysiol. 2016;2:295–303.CrossRefPubMed
5.
Zurück zum Zitat Wu M, Gabriels J, Khan M, Shaban N, D'Amato S, Liu CF, et al. Left atrial thrombus and dense spontaneous echocardiographic contrast in patients on continuous direct oral anticoagulant therapy undergoing catheter ablation of atrial fibrillation: comparison of dabigatran, rivaroxaban, and apixaban. Heart Rhythm. 2018 April;15(4):496–502.CrossRefPubMed Wu M, Gabriels J, Khan M, Shaban N, D'Amato S, Liu CF, et al. Left atrial thrombus and dense spontaneous echocardiographic contrast in patients on continuous direct oral anticoagulant therapy undergoing catheter ablation of atrial fibrillation: comparison of dabigatran, rivaroxaban, and apixaban. Heart Rhythm. 2018 April;15(4):496–502.CrossRefPubMed
6.
Zurück zum Zitat Lip GY, Hammerstingl C, Marin F, Cappato R, Meng IL, Kirsch B, et al. Rationale and design of a study exploring the efficacy of once-daily oral rivaroxaban (X-TRA) on the outcome of left atrial/left atrial appendage thrombus in nonvalvular atrial fibrillation or atrial flutter and a retrospective observational registry providing baseline data (CLOT-AF). Am Heart J. 2015;169:464–71. e462CrossRefPubMed Lip GY, Hammerstingl C, Marin F, Cappato R, Meng IL, Kirsch B, et al. Rationale and design of a study exploring the efficacy of once-daily oral rivaroxaban (X-TRA) on the outcome of left atrial/left atrial appendage thrombus in nonvalvular atrial fibrillation or atrial flutter and a retrospective observational registry providing baseline data (CLOT-AF). Am Heart J. 2015;169:464–71. e462CrossRefPubMed
7.
Zurück zum Zitat Lip GY, Hammerstingl C, Marin F, Cappato R, Meng IL, Kirsch B, et al. Left atrial thrombus resolution in atrial fibrillation or flutter: results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF). Am Heart J. 2016;178:126–34.CrossRefPubMed Lip GY, Hammerstingl C, Marin F, Cappato R, Meng IL, Kirsch B, et al. Left atrial thrombus resolution in atrial fibrillation or flutter: results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF). Am Heart J. 2016;178:126–34.CrossRefPubMed
8.
Zurück zum Zitat Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro heart survey on atrial fibrillation. Chest. 2010;137:263–72.CrossRefPubMed Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro heart survey on atrial fibrillation. Chest. 2010;137:263–72.CrossRefPubMed
9.
Zurück zum Zitat Jaber WA, Prior DL, Thamilarasan M, Grimm RA, Thomas JD, Klein AL, et al. Efficacy of anticoagulation in resolving left atrial and left atrial appendage thrombi: a transesophageal echocardiographic study. Am Heart J. 2000;140:150–6.CrossRefPubMed Jaber WA, Prior DL, Thamilarasan M, Grimm RA, Thomas JD, Klein AL, et al. Efficacy of anticoagulation in resolving left atrial and left atrial appendage thrombi: a transesophageal echocardiographic study. Am Heart J. 2000;140:150–6.CrossRefPubMed
10.
Zurück zum Zitat Vidal A, Vanerio G. Dabigatran and left atrial appendage thrombus. J Thromb Thrombolysis. 2012;34:545–7.CrossRefPubMed Vidal A, Vanerio G. Dabigatran and left atrial appendage thrombus. J Thromb Thrombolysis. 2012;34:545–7.CrossRefPubMed
11.
Zurück zum Zitat Takasugi J, Yamagami H, Okata T, Toyoda K, Nagatsuka K. Dissolution of the left atrial appendage thrombus with rivaroxaban therapy. Cerebrovasc Dis. 2013;36:322–3.CrossRefPubMed Takasugi J, Yamagami H, Okata T, Toyoda K, Nagatsuka K. Dissolution of the left atrial appendage thrombus with rivaroxaban therapy. Cerebrovasc Dis. 2013;36:322–3.CrossRefPubMed
12.
Zurück zum Zitat Hammerstingl C, Potzsch B, Nickenig G. Resolution of giant left atrial appendage thrombus with rivaroxaban. Thromb Haemost. 2013;109:583–4.CrossRefPubMed Hammerstingl C, Potzsch B, Nickenig G. Resolution of giant left atrial appendage thrombus with rivaroxaban. Thromb Haemost. 2013;109:583–4.CrossRefPubMed
13.
14.
Zurück zum Zitat Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18:1609–78.CrossRefPubMed Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18:1609–78.CrossRefPubMed
15.
Zurück zum Zitat January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1–76.CrossRefPubMed January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1–76.CrossRefPubMed
16.
Zurück zum Zitat Bernhardt P, Schmidt H, Hammerstingl C, Hackenbroch M, Sommer T, Luderitz B, et al. Fate of left atrial thrombi in patients with atrial fibrillation determined by transesophageal echocardiography and cerebral magnetic resonance imaging. Am J Cardiol. 2004;94:801–4.CrossRefPubMed Bernhardt P, Schmidt H, Hammerstingl C, Hackenbroch M, Sommer T, Luderitz B, et al. Fate of left atrial thrombi in patients with atrial fibrillation determined by transesophageal echocardiography and cerebral magnetic resonance imaging. Am J Cardiol. 2004;94:801–4.CrossRefPubMed
17.
Zurück zum Zitat Lip GY, Lane DA. Matching the NOAC to the patient: remember the modifiable bleeding risk factors. J Am Coll Cardiol. 2015;66:2282–4.CrossRefPubMed Lip GY, Lane DA. Matching the NOAC to the patient: remember the modifiable bleeding risk factors. J Am Coll Cardiol. 2015;66:2282–4.CrossRefPubMed
18.
Zurück zum Zitat Berger M, Schweitzer P. Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: a retrospective analysis. Am J Cardiol. 1998;82:1545–7.CrossRefPubMed Berger M, Schweitzer P. Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: a retrospective analysis. Am J Cardiol. 1998;82:1545–7.CrossRefPubMed
19.
Zurück zum Zitat Nagarakanti R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, Aikens TH, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011;123:131–6.CrossRefPubMed Nagarakanti R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, Aikens TH, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011;123:131–6.CrossRefPubMed
Metadaten
Titel
Left atrial thrombus despite continuous direct oral anticoagulant or warfarin therapy in patients with atrial fibrillation: insights into rates and timing of thrombus resolution
verfasst von
Michael S. Wu
James Gabriels
Mohammad Khan
Nada Shaban
Salvatore A. D’Amato
Christopher F. Liu
Steven M. Markowitz
James E. Ip
George Thomas
Parmanand Singh
Bruce B. Lerman
Apoor Patel
Jim W. Cheung
Publikationsdatum
04.08.2018
Verlag
Springer US
Erschienen in
Journal of Interventional Cardiac Electrophysiology / Ausgabe 2/2018
Print ISSN: 1383-875X
Elektronische ISSN: 1572-8595
DOI
https://doi.org/10.1007/s10840-018-0432-1

Weitere Artikel der Ausgabe 2/2018

Journal of Interventional Cardiac Electrophysiology 2/2018 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.